PrEP Daily Use, Subscription

“Descovy” Emtricitabine Tenofovir Alafenamide (TAF)Descovy is a combination antiretroviral medication containing emtricitabine and tenofovir alafenamide (TAF) used to treat and prevent HIV infection as pre-exposure prophylaxis (PrEP) in high-risk individuals.

Descovy is only approved for daily use.

Descovy is only approved for daily PrEP, it has not been approved on-demand, or event-based PrEP.

What is the main difference between Truvada vs Descovy?

Descovy and Truvada are both combination antiretroviral medications used for the treatment and prevention of HIV infection. The key difference between them lies in their composition:

1. Truvada: Contains emtricitabine and tenofovir disoproxil fumarate (TDF) – daily use only
2. Descovy: Contains emtricitabine and tenofovir alafenamide (TAF) – on-demand and daily use.

Both medications contain emtricitabine, but the difference lies in the form of tenofovir they contain. Tenofovir alafenamide (TAF) in Descovy is a newer prodrug of tenofovir, which is scentifically proven for improved renal safety and lower risk of bone mineral density loss

This difference in composition leads to some advantages for Descovy over Truvada:

1. Improved renal safety: TAF in Descovy has been shown to be associated with a lower risk of kidney-related side effects compared to TDF in Truvada.
2. Better bone safety: Descovy is associated with a lower risk of bone mineral density loss compared to Truvada, reducing the likelihood of fractures.

However, it’s important to note that both medications are effective in treating and preventing HIV infection, and the choice between them should be based on individual patient factors and medical history.

Consult our healthcare provider to determine the best option for your specific situation.